Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

New York-based cosmetic dermatologist Dr Michele Green told DailyMail.com that 'Ozempic mouth' is something she is seeing ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

BRITS could soon be able to get Ozempic-style fat jabs from high street pharmacies, according to reports. Drugs like Wegovy ...

The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It is also working on separate guidelines for children and adolescents.

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...